In a report released today, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP), with a price target of $10. The company’s shares closed yesterday at $8.10. According to TipRanks.com, Lawson is a 4-star analyst